Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA
Cancers · 22.12.2025 · 18 (1) · 35
DOI: 10.3390/cancers18010035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 22.12.2025. Verfasst von Rafi Kabarriti und 20 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10467, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Surveillance for anal squamous cell carcinoma (ASCC) recurrence relies on clinical examination and imaging. Post-treatment edema, fibrosis, and inflammation can result in clinically indeterminate findings (CIFs) that delay diagnosis and increase patient and system burden. Circulating tumor tissue-modified viral (TTMV)-HPV DNA offers a biologically specific, noninvasive biomarker that may clarify equivocal assessments.
Methods
In this multi-center retrospective study, 233 patients with HPV-associated ASCC were evaluated, including 185 with ≥1 post-treatment TTMV-HPV DNA test. CIFs were defined as exams or imaging results not definitively positive or negative for disease, and were paired with subsequent TTMV-HPV DNA tests. Concordance was defined by prespecified follow-up windows comparing TTMV-HPV DNA results with subsequent clinical outcomes.
Results
Ninety patients (39%) experienced 214 CIFs, arising from exams (46%, 98) or imaging (54%, 116). Indeterminate rates by assessment were 7% for exams, 17% for imaging, and 1.3% for TTMV-HPV DNA testing. Overall, 52 CIF/TTMV-HPV DNA pairs were eligible for analysis, and TTMV-HPV DNA resolved disease status accurately for 48/52 (92%, 95% CI: 81.5–97.9). Negative tests predicted cancer-free status for 37/41 CIFs (90%), while 100% of positive tests (11/11) were concordant with clinically confirmed recurrence. In 73% of positive cases (8/11), TTMV-HPV DNA was the first indication of recurrence (median lead-time 29 days; IQR 25–147).
Conclusions
TTMV-HPV DNA testing reliably clarifies clinically indeterminate findings during ASCC surveillance, demonstrating high accuracy (92%) and earlier detection of recurrence. These data support integration into post-treatment management to reduce diagnostic uncertainty and guide timely care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10467, USA.
- Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT 84113, USA.
- Naveris, Inc., Waltham, MA 02451, USA.
- Cancer Care Northwest, Spokane Valley, WA 99216, USA.
- Scripps Health, San Diego, CA 92121, USA.
- California Protons Cancer Therapy Center, San Diego, CA 92121, USA.
ORCID-Profile: Shane Lloyd, James Jabalee, Corbin Jacobs, Ray Lin, Cammie Nguyen, Michael Rutenberg, Kasha Neff, Tiffany M Juarez
Zitieren
APA
Kabarriti, R., Lloyd, S., Jabalee, J., Gay, L. M., Slater, T., Guzman, K., Jacobs, C., Inocencio, S., Lin, R., Nguyen, C., MacEwan, I., Crawford, A. H., Rutenberg, M., Singh, J., Ross, J., Kim-Wang, S., Matthiesen, C., Neff, K., Liu, G. F., …, & Liauw, S. L. (2025). Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA. Cancers, 18(1), 35. https://doi.org/10.3390/cancers18010035
Vancouver
Kabarriti R, Lloyd S, Jabalee J, Gay LM, Slater T, Guzman K, et al. Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA. Cancers. 2025;18(1):35. doi:10.3390/cancers18010035
BibTeX
@article{Kabarriti2025,
author = {Kabarriti, Rafi and Lloyd, Shane and Jabalee, James and Gay, Laurie M and Slater, Tyler and Guzman, Kayleen and Jacobs, Corbin and Inocencio, Sean and Lin, Ray and Nguyen, Cammie and MacEwan, Iain and Crawford, Alexandra H and Rutenberg, Michael and Singh, Jaswinder and Ross, Jennifer and Kim-Wang, Sophia and Matthiesen, Chance and Neff, Kasha and Liu, Gene-Fu and Juarez, Tiffany M and Liauw, Stanley L},
title = {Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA},
journal = {Cancers},
year = {2025},
volume = {18},
number = {1},
pages = {35},
doi = {10.3390/cancers18010035}
}
EUVIMED